#	Pagina
attuale pagina	/open-h2020/projects/211020/index.html

Opendata, web and dolomites

Super-Vaccine SIGNED

Exploring the potential applications of live viral vaccine encoded small-hairpin-RNAs in improving both vaccine safety and efficacy through RNA-interference and stimulation of the innate immune system

Total Cost €

EC-Contrib. €

Partnership

Views

Super-Vaccine project word cloud

Explore the words cloud of the Super-Vaccine project. It provides you a very rough idea of what is the project "Super-Vaccine" about.

shrnas intrinsic live roadmap immune designed inhibit ongoing doses security rnas beneficial appropriately rnai levels progression safety efficacy healthcare trials launched stimulation mind recombination strategy 2016 wt vitro reducing innate propagation interference feasible harmony vaccine primary viral lower express interventions spread potency perspective meet modifying manufacturing strain innovation instrumental reduce global attenuated followed explored societal tomorrow basis replication cyprinid viruses food desirable vaccines inducers economically strategic hairpin expression interferon rna genetically programs occurrences potent efforts priorities circulating outline exclusively ifn vivo capacity vaccination market explore herpesvirus virus functioning disease recombine strains small ultimately wild

Project "Super-Vaccine" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITE DE LIEGE Organization address address: PLACE DU 20 AOUT 7 city: LIEGE postcode: 4000 website: www.ulg.ac.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Belgium [BE]
Total cost	160˙800 €
EC max contribution	160˙800 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2016
Funding Scheme	MSCA-IF-EF-CAR
Starting year	2018
Duration (year-month-day)	from 2018-09-19 to 2020-09-18

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITE DE LIEGE UNIVERSITE DE LIEGE Organization address address: PLACE DU 20 AOUT 7 city: LIEGE postcode: 4000 website: www.ulg.ac.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (LIEGE)	coordinator	160˙800.00

Map

Project objective

Live vaccines represent one of the most important and effective interventions against the spread of viral disease. As such, they are instrumental in addressing ongoing societal challenges in areas such as healthcare and global food security. However, their capacity to genetically recombine with wild type (WT) viruses circulating in the field remains a primary safety concern. Modifying live vaccine strains to reduce such occurrences would be highly desirable from a safety perspective. Also efforts to enhance the intrinsic potency of vaccine strains would be very beneficial. This would facilitate the use of much lower doses, while reducing the manufacturing resources required to meet market needs and the cost of vaccination programs.

With this in mind, this project will explore a novel strategy to improve both the safety and efficacy of live viral vaccine strains by modifying them to express small-hairpin-RNAs (shRNAs), which can be designed to:

i) Exclusively inhibit WT virus replication/propagation via RNA-interference (RNAi), thus reducing the levels of WT available for recombination with vaccine strains during vaccination i.e. improving safety

ii) Increase live vaccine strain stimulation of the innate immune system by functioning as potent inducers of Type-1 Interferon (IFN-I) expression during vaccination i.e. enhancing efficacy

This novel strategy will be explored by modifying an existing attenuated Cyprinid herpesvirus-3 vaccine strain to express appropriately designed shRNAs, followed by an assessment of their impact on both WT virus replication and IFN-I expression in-vitro, providing a basis for future progression to in-vivo trials.

Ultimately, if feasible, this novel vaccine design strategy may be applied in the control of many economically important viruses. Also elements of this project are in harmony with the “Strategic European Roadmap for the Vaccines of Tomorrow” launched in 2016 to outline specific EU priorities in future vaccine innovation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SUPER-VACCINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SUPER-VACCINE" are provided by the European Opendata Portal: CORDIS opendata.